Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-11
2006-04-11
Romeo, David (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S303000, C530S350000, C530S399000, C424S422000
Reexamination Certificate
active
07026292
ABSTRACT:
The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions are also provided.
REFERENCES:
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5108753 (1992-04-01), Kuberasampath et al.
patent: 5162114 (1992-11-01), Kuberasampath et al.
patent: 5166058 (1992-11-01), Wang et al.
patent: 5171574 (1992-12-01), Kuberasampath et al.
patent: 5258494 (1993-11-01), Oppermann et al.
patent: 5324819 (1994-06-01), Oppermann et al.
patent: 5344654 (1994-09-01), Rueger et al.
patent: 5354557 (1994-10-01), Oppermann et al.
patent: 5459047 (1995-10-01), Wozney et al.
patent: 5461034 (1995-10-01), Rodan et al.
patent: 5674844 (1997-10-01), Kuberasampath et al.
patent: 5691305 (1997-11-01), Baylink et al.
patent: 5948428 (1999-09-01), Lee et al.
patent: 6048964 (2000-04-01), Lee et al.
patent: 0 436 469 (1991-07-01), None
patent: 0 514 720 (1992-11-01), None
patent: 9048738 (1997-02-01), None
patent: WO 91/18558 (1991-12-01), None
patent: WO 92/09697 (1992-06-01), None
patent: WO 92/21365 (1992-12-01), None
patent: WO 93/05823 (1993-04-01), None
patent: WO 95/05846 (1995-03-01), None
patent: WO 95/16034 (1995-06-01), None
patent: WO 95/16035 (1995-06-01), None
patent: WO 95/24210 (1995-09-01), None
Hock et al. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology. Jan. 1998;122(1):254-60.
Kingsley D M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes and Development, (Jan. 1994) 8 (2) 133-46.
Shah M; Foreman D M; Ferguson M W. Neutralisation of TGF-beta 1 and TGf-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J. Cell Sci., (Mar. 1995) 108 ( Pt 3) 985-1002.
Vukicevic et al. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). Proc Natl Acad Sci U S A Aug. 20, 1996;93(17):9021-6.
Nathan et al. Cytokines in context. Journal of Cell Biology, (Jun. 1991) 113 (5) 981-986.
Alberts et al., Molecular Biology of the Cell, Jan. 1994, Garland Publishing, Inc., New York, NY, page(s) 1142, 1144-1145.
Ogawa et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem. Jul. 15, 1992;267(20):14233-7.
Wozney et al. “Bone Morphogenetic Proteins”, Chapter 20, In, Handbook of Experimental Pharmacology: Physiology and Pharmacology of Bone. Berlin: Springer-Verlag. 1993, vol. 107, paragraph bridging pp. 726-727.
Reddi et al. Bone induction by osteogenin and bone morphogenetic proteins. Biomaterials, (Jul. 1990) 11 33-4.
Li et al. Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Ther. Sep. 2003;10(20):1735-43.
Yeh et al. Osteogenic protein-1 and insulin-like growth factor 1 synergistically stimulate rat osteoblastic cell differentiation and proliferation. Endocrinology. Oct. 1997;138(10):4181-90.
Andrews, P. W. et al., “Inhibition of Proliferation and Induction of Differentiation of Pluripotent Human Embryonal Carcinoma Cells by Osteogenic Protein-1 (Or Bone Morphogenetic Protein-7),”Laboratory Investigation 71:243-251 (1994).
Benayahu, D., et al., “Differential Effects of Retinoic Acid and Growth Factors on Osteoblastic Markers and CD10/NEP Activity in Stromal-Derived Osteoblasts,”Journal of Cellular Biochemistry 56:62-73 (1994).
Benayahu, D., et al., “PTH and 1,25(OH) Vitamin D Priming To Growth Factors Differentially Regulates The Osteoblastic Markers in MBA-15 Clonal Sobpopulations,”Biochemical and Biophysical Research Communications 210:197-204 (May 5, 1995).
Canalis, Ernesto, et al., “Bone Morphogenetic Protein 2 Increases Insulin-like Growth Factor I and II Transcripts and Polypeptide Levels in Bone Cell Cultures,”Journal of Bone and Mineral Research 9:1999-2005(1994).
Chen, P. et al., “Osteogenic Protein-1 Promotes Growth and Maturation of Chick Sternal Chondrocytes in Serum-free Cultures, Osteogneic protein-1 promotes growth and maturation of chick sternal chodrocytes in serum-free cultures,”Journal of Cell Science 108:105-114 (Jan. 1995).
Cook, Stephen D., et al., “Recombinant Human Bone Morphogenetic Protein- 7 Induces Healing in a Canine Long-Bone Segmental Defect Model,”Clinical Orthopaedics&Related Research 201:302-312 (Apr. 1994).
Cook, Stephen D., et al., “The Effect of Recombinant Human Osteogenic Protein-1 on Healing of Large Segmental Bone Defects,”The Journal of Bone and Joint Surgery 76-A:827-838 (Jun. 1994).
Cook, Stephen D., et al., “In Vivo Evaluation of Recombinant Human Osteogenic Protein (rhOP-1) Implants as a Bone Graft Substitute for Spinal Fusions,”Spine 19:1655-63 (Aug. 1, 1994).
Cook, Stephen D., et al., “Effect of Recombinant Human Osteogenic Protein-1 on Healing of Segmental Defects in Non-Human Primates,”The Journal of Bone and Joint Surgery 77-A:734-750 (May 1995).
Dudley, A.T. et al., “A Requirement for Bone Morphogenetic Protein-7 During Development of the Mammalian Kidney and Eye,”Genes and Development 9:2795-2807 (Nov. 1995).
Gabbitas, Bari, et al., “Bone Morphogenetic Protein-2 Inhibits the Synthesis of Insulin-Like Growth Factor-Binding Protein-5 in Bone Cell Cultures,”The Endocrine Society 136:2397-2403 (1995).
Gitelman, Stephen E., t al., “Recombinant Vgr- 1/BMP-6-expressing Tumors Induce Fibrosis and Endochondral Bone Formation In Viv,” J. Cell Biol. 126:1595-1609 (1994).
Guerne, Pierre-André´, et al., “Growth Factor Responsiveness of Human Articular Chondrocytes: Distinct Profiles in Primary Chondrocytes, Subcultured Chondrocytes, and Fibroblasts,”J. Cell. Phys. 158:476-484 (1994).
Hammerman, Marc R., “Growth Factors in Renal Development,”Seminars in Nephrology 15:291-299 (Jul. 1995).
Helder, M.N., et al., “Expression Pattern of Osteogenic Protein-1 (Bone Morphogenetic Protein-7) in Human and Mouse Development,”J. Histochem. and Cytochem. 43:1035-44 (Oct. 1995).
Hentunen, T.A. et al., “Effects of Recombinant Human Osteogenic Protein-1 on the Differentiation of Osteoclast-like Cells and Bone Resorption,”Biochemical and Biophysical Research Communications 209:433-443 (Apr. 17, 1995).
Hiraki, Yuji, et al., “Bone Morphogenetic Proteins (BMP-2 and BMP-3) Promote Growth and Expression of the Differentiated Phenotype of Rabbit Chondrocytes and Osteoblastic MC3T3-E1 Cells In Vitro,”Journal of Bone and Mineral Research 6:1373-1385 (Dec. 1991).
Kawamura, Morio, et al., “Growth Factors, Mitogens, Cytokines, and Bone Morphogenetic Protein in Induced Chondrogenesis in Tissue Culture,”Developmental Biology 130:435-442 (1988).
Kirker-Head, C.A., et al., “Recombinant Bone Morphogenetic Proteins: Novel Substanc
Lee John C.
Yeh Lee-Chuan C.
Fish & Neave IP Group Ropes & Gray LLP
Haley Jr. James F.
Mangasarian Karen
Romeo David
Stryker Corporation
LandOfFree
Compositions and therapeutic methods using morphogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and therapeutic methods using morphogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and therapeutic methods using morphogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3542721